Sequencing Agents for the Treatment of Pancreatic NETs

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 3)
Volume 3
Issue 1

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).

Learn more about research into the treatment of pancreatic NETs > >

Articles in this issue
Unanswered Questions Regarding the Treatment of Pancreatic NETs
Unanswered Questions Regarding the Treatment of Pancreatic NETs
Targeted Agents and Combinations Being Studied in Pancreatic NETs
Targeted Agents and Combinations Being Studied in Pancreatic NETs
Sequencing Agents for the Treatment of Pancreatic NETs
Sequencing Agents for the Treatment of Pancreatic NETs
Research on Epidemiology of GIST Identifies Risk Factors
Research on Epidemiology of GIST Identifies Risk Factors
Antiangiogenic Strategies for mCRC Need Further Exploration
Antiangiogenic Strategies for mCRC Need Further Exploration
Coping With Comorbidities in Hepatocellular Cancer
Coping With Comorbidities in Hepatocellular Cancer
Strategies in Surveillance: Hepatocellular Carcinoma
Strategies in Surveillance: Hepatocellular Carcinoma
Immunotherapy and Viral Therapy for Pancreatic Cancer
Immunotherapy and Viral Therapy for Pancreatic Cancer

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Jacobson Discusses Second and Third-Line Options for DLBCL

Jacobson Discusses Second and Third-Line Options for DLBCL

Targeted Oncology Staff
April 19th 2025
Article

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Read More

Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC

Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC

Targeted Oncology Staff
April 18th 2025
Article

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.

Read More

Analysis Illuminates CAR T-Cell Optimization for CLL

Analysis Illuminates CAR T-Cell Optimization for CLL

Morgan Bayer
April 17th 2025
Article

Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

Read More

Hoffmann Examines Data for 17p Deletion in Treatment-Naive CLL

Hoffmann Examines Data for 17p Deletion in Treatment-Naive CLL

Targeted Oncology Staff
April 17th 2025
Article

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic leukemia.

Read More

Immunotherapy Inches Forward in Head and Neck Cancer Trials

Immunotherapy Inches Forward in Head and Neck Cancer Trials

Tony Berberabe, MPH
April 16th 2025
Article

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated, even in phase 3 trials.

Read More

AI May Replace the Front Desk in Health Care

AI May Replace the Front Desk in Health Care

Jock Putney
April 15th 2025
Article

AI is no longer in the realm of speculative science fiction—it’s here, and it’s moving fast.

Read More